This post was originally published on this site A Phase 2b clinical trial evaluating ModraDoc006/r, Modra Pharmaceutical’s investigational oral treatment for metastatic castration-resistant prostate cancer, has started dosing patients, the company announced. ModraDoc006/r is a tablet formulation of the chemotherapy docetaxel. Doctors administer it with ritonavir, which increases the amount of docetaxel absorbed by the body.…
This post was originally published on this site Xynomic Pharmaceuticals has filed a request with U.S. Food and Drug Administration (FDA) asking that abexinostat, its lead therapeutic candidate for relapsed or refractory follicular lymphoma, be given fast track designation. The designation is given to therapies that show potential to treat serious health conditions or those with unmet…
This post was originally published on this site Zytiga (abiraterone acetate), a kind of hormone therapy, has been added to the World Health Organization’s (WHO) Essential Medicines List for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Updated every two years since 1977, the publication focuses on recommendations for malignancies such as prostate cancer and other…
This post was originally published on this site Not all “pre-cancerous” ovarian lesions progress to full-fledged cancer, a new study reports. If confirmed, these results could allow for better identification of ovarian cancer at its very early stages, and potentially strengthen preventative care for this disease. The study was published in The Journal of Pathology and…
This post was originally published on this site The clonoSEQ Assay — a test that detects cancer cells present in very small numbers in a patient’s bone marrow, blood, or tissue sample — now is available to New York residents with multiple myeloma and other B-cell blood cancers. The announcement by Adaptive Biotechnologies follows an approval by…
This post was originally published on this site Two initial patient groups have been expanded and four others added to a Phase 1b trial assessing the combination therapy Cabometyx (cabozantinib) and Tecentriq (atezolizumab) in people with locally advanced or metastatic solid tumors, Exelixis has announced. The multi-center, open-label COSMIC-021 trial (NCT03170960) is evaluating the safety, tolerability, preliminary efficacy,…
This post was originally published on this site Using Keytruda (pembrolizumab) in combination with chemotherapy increased the percentage of patients showing no signs of breast cancer after completing a course of neoadjuvant therapy — treatment to shrink a tumor — and surgery, interim analysis of a Phase 3 trial shows. This marks the first time…
This post was originally published on this site AZTherapies has completed enrollment for its Phase 3 COGNITE trial, testing the safety and efficacy of its investigational ALZT-OP1 for the treatment of early Alzheimer’s disease (AD). A total of 620 participants were enrolled following the screening of 1,800 patients, the company said. “With the COGNITE trial…
This post was originally published on this site Using Jakafi (ruxolitinib) to treat a woman with polycythemia vera (PV; a blood cancer) led to complete resolution of her cutaneous sarcoidosis, and to mild reduction of her lung nodules, according to a case report. The findings suggest a new therapeutic strategy, especially for patients with cutaneous sarcoidosis,…
This post was originally published on this site The Phase 1 trial evaluating Betalutin — an investigational tumor-targeting antibody labeled with a type of radiation — in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is now fully enrolled, its developer, Nordic Nanovector, announced. The ongoing LYMRIT 37-05 trial (NCT02658968) includes 18 patients who are…
